BioSpace News Archive

Neurophth Therapeutics, Inc. (“Neurophth”) today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on the in-vivo gene replacement therapy NFS-02 (rAAV2-ND1), for the treatment of Leber hereditary optic neuropathy (LHON) associated with ND1 mutation.

Molecular Hydrogen Inhalation therapy is now extensively used for its many health benefits, such as reducing inflammation, improving cellular function, and protecting against oxidative stress.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down to focus on his new position as Managing Director at Bain Capital Life Sciences.

Catalent, Inc. today announced that current board member and lead independent director J. Martin (“Marty”) Carroll has been unanimously selected by its Board of Directors to succeed John Chiminski and serve as Chair following Mr. Chiminski’s retirement.

Septerna today announced the establishment of its cross-functional scientific and drug discovery advisory board with seasoned industry drug hunters and leading academic GPCR biology and pharmacology scientists.

Ubiquitome’s next generation real time PCR device system, the Liberty16 Pro, has been given Emergency Use Approval (EUA) by the United States Food and Drug Administration (FDA).

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after leading the company through a significant period of revitalization and growth for more than seven years.

Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT).

ICU Medical, (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the J.P. Morgan 41st Annual Healthcare Conference, being held in San Francisco, CA, January 9-12, 2023.

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices announced the U.S. Food and Drug Administration’s (FDA) clearance of Sofwave’s SUPERB™ technology to be used for the short-term improvement in the appearance of cellulite.